Amphastar Pharmaceuticals, Inc. vs Evotec SE: Examining Key Revenue Metrics

Pharma Giants' Revenue Growth: Amphastar vs Evotec

__timestampAmphastar Pharmaceuticals, Inc.Evotec SE
Wednesday, January 1, 201421046100089496000
Thursday, January 1, 2015251519000127677000
Friday, January 1, 2016255165000164507000
Sunday, January 1, 2017240175000257630000
Monday, January 1, 2018294666000375405000
Tuesday, January 1, 2019322357000446437000
Wednesday, January 1, 2020349846000500924000
Friday, January 1, 2021437768000618034000
Saturday, January 1, 2022498987000751448000
Sunday, January 1, 2023644395000781426000
Loading chart...

In pursuit of knowledge

Amphastar Pharmaceuticals, Inc. vs Evotec SE: A Revenue Journey

In the competitive landscape of pharmaceuticals, revenue growth is a key indicator of success. Amphastar Pharmaceuticals, Inc. and Evotec SE have been on intriguing trajectories since 2014. Amphastar's revenue has surged by over 200%, from approximately $210 million in 2014 to an impressive $644 million in 2023. Meanwhile, Evotec SE has experienced a remarkable growth of nearly 800%, starting from a modest $89 million in 2014 and reaching $781 million by 2023.

Key Insights

  • Amphastar's Growth: The company saw a steady increase, with a notable jump of 29% from 2021 to 2022.
  • Evotec's Expansion: Evotec's revenue more than doubled between 2017 and 2023, highlighting its aggressive market expansion.
    This data underscores the dynamic nature of the pharmaceutical industry, where strategic growth and market adaptation are crucial for sustained success.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025